https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-09-01 / Cancer Res. 2006 Sep;66(17):8887-96
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-09-01 / Cancer Res. 2006 Sep;66(17):8887-962006-09-01 00:00:002019-02-15 08:59:58Induction of potent antitumor immunity by intratumoral injection of interleukin 23-transduced dendritic cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-09-01 / J. Immunother. 2006 Sep-Oct;29(5):545-57
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-09-01 / J. Immunother. 2006 Sep-Oct;29(5):545-572006-09-01 00:00:002019-02-15 09:19:45Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-09-01 / Urol. Oncol. 2006 Sep-Oct;24(5):434-41
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-09-01 / Urol. Oncol. 2006 Sep-Oct;24(5):434-412006-09-01 00:00:002019-02-15 09:24:13Immunotherapy for prostate cancer using prostatic acid phosphatase loaded antigen presenting cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-09-01 / Urol. Oncol. 2006 Sep-Oct;24(5):413-8
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-09-01 / Urol. Oncol. 2006 Sep-Oct;24(5):413-82006-09-01 00:00:002019-02-15 09:24:14Basic overview of current immunotherapy approaches in urologic malignancy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-08-16 / J Transl Med 2006 Aug;4:36
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-08-16 / J Transl Med 2006 Aug;4:362006-08-16 00:00:002019-02-15 08:49:33Improved overall survival in dendritic cell vaccination-induced immunoreactive subgroup of advanced melanoma patients
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-08-01 / Cancer Res. 2006 Aug;66(15):7678-85
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-08-01 / Cancer Res. 2006 Aug;66(15):7678-852006-08-01 00:00:002019-02-15 08:35:27Targeting the heat shock factor 1 by RNA interference: a potent tool to enhance hyperthermochemotherapy efficacy in cervical cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-08-01 / Hematol. Oncol. Clin. North Am. 2006 Aug;20(4):965-83, xi
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-08-01 / Hematol. Oncol. Clin. North Am. 2006 Aug;20(4):965-83, xi2006-08-01 00:00:002019-02-15 09:24:15Immunotherapy for prostate cancer: what’s the future?
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-08-01 / J. Virol. 2006 Aug;80(15):7522-34
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-08-01 / J. Virol. 2006 Aug;80(15):7522-342006-08-01 00:00:002019-02-15 09:22:12Newcastle disease virus exerts oncolysis by both intrinsic and extrinsic caspase-dependent pathways of cell death
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-08-01 / Mol. Cancer Ther. 2006 Aug;5(8):1975-85
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-08-01 / Mol. Cancer Ther. 2006 Aug;5(8):1975-852006-08-01 00:00:002006-08-01 00:00:00Antitumor immune response induced by i.t. injection of vector-activated dendritic cells and chemotherapy suppresses metastatic breast cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-07-15 / Int. J. Cancer 2006 Jul;119(2):328-38
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-07-15 / Int. J. Cancer 2006 Jul;119(2):328-382006-07-15 00:00:002020-06-23 09:36:30Tumor selective replication of Newcastle disease virus: association with defects of tumor cells in antiviral defence
